Skip to main content

Drug Interactions between ensartinib and nafcillin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nafcillin ensartinib

Applies to: nafcillin and ensartinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with moderate to potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of ensartinib, which is primarily metabolized via the isoenzyme in vitro. Clinical data characterizing the extent of this interaction and data with less potent inducers are not available.

MANAGEMENT: Concomitant use of ensartinib with moderate to potent inducers of CYP450 3A4 should generally be avoided. The possibility of diminished therapeutic effects should be considered. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

Drug and food/lifestyle interactions

Moderate

nafcillin food/lifestyle

Applies to: nafcillin

You may experience reduced absorption of nafcillin in the presence of food. The effectiveness of the antibiotic may be reduced. Nafcillin should be administered one hour before or two hours after meals. This will make it easier for your body to absorb the medication. Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer